

Product Update

levonorgestrel (Levosert[®]) 20 micrograms/24 hours intrauterine delivery system SMC No. (1058/15)

Actavis UK Ltd

08 May 2015

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

levonorgestrel (Levosert[®]) intrauterine delivery system is accepted for use within NHS Scotland.

Indication under review: Contraception. Heavy menstrual bleeding.

Levosert[®] may be particularly useful in women with heavy menstrual bleeding requiring (reversible) contraception.

Levosert[®] intrauterine delivery system (IUS) contains the same total amount of levonorgestrel with the same release profile as an existing levonorgestrel-containing IUS at a lower unit cost.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 18 March 2015.

Chairman, Scottish Medicines Consortium